👁️ "Statins thus emerge as the class with the largest anti-inflammatory effect, leading to an additional −0.65 mg/L absolute decrease of CRP concentrations 👌We FAILED to find an ASSOCIATION between REDUCTIONS in LDL-C and CHANGES IN CRP levels with this drug class"

👁️"Atherosclerosis is also an inflammatory degenerative disease 👌PCSK9 affects the atherosclerotic process NOT ONLY VIA LIPID METABOLISM but also through its effects on the COAGULATION fibrinolytic system, INFLAMMATION, platelets and endothelial cells and function"

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia NEJM LipidMIR nejm.org/doi/full/10.10…

Drug target mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention. Well done Benoit Arsenault and Eloi Gagnon! 🔗atherosclerosis-journal.com/article/S0021-… European Atherosclerosis Society Elsevier Cardiology

Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of MI LipidMIR Rosa Fernandez Míriam Martín Toro Armando Oterino Manzanas jacc.org/doi/10.1016/j.…

#EASCongress2024 in review 🎥 What impact does Lp(a) have on CV risk? Can’t wait to see the CV outcomes of these clinical trials 👇🏼 European Atherosclerosis Society EAS Congress #medtwitter #cardiotwitter

Clinical interventions suggest ApoB-containing lipoprotein may be more relevant than triglyceride and cholesterol composition 🔗atherosclerosis-journal.com/article/S0021-… Elsevier Cardiology European Atherosclerosis Society #CVPrev #EASSoMe

👉Los últimos estudios presentados en el control de lípidos ☝️ Repasamos junto a la Dra. Cecilia Bahit (Cecilia Bahit) los últimos estudios en lípidos con fármacos innovadores con mecanismos de acción sobre el ARN mensajero Medscape ES Medscape Mariana LM #vacúnate #ValoraLosRiesgos

The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer link.springer.com/article/10.100… Creo que todas las personas que se dedican a la obesidad tendrían que tener formación en las nuevas terapias o fármacos que se van a utilizar en el presente y futuro

(Diabetes Care) Eficacia y seguridad de los aGLP1 en pac con DM2 obesidad diabetesjournals.org/care/article/d… Revisión

Semaglutida versus agonistas GLP-1. Efectividad, seguridad y calidad de vida en pacientes con diabetes mellitus 2. Estudio SEVERAL Rosana Castelo Jose Seijas Amigo José R. Juanatey Farm Hosp.2022;46(6):372-379 #RevistaFarmaciaHospitalaria #HospitalPharmacy revistafarmaciahospitalaria.es/es-pdf-X113063…

El tsunami de la terapia genica se acerca 677 programas. 210 empresas. ¿Estamos preparados? Medicamentos de Terapia Avanzada - SEFH S.E.F.H

Clinical inertia is ☠️ our patients ‼️ Lipid lowering therapy should be considered start at the first sign of subclinical ASCVD 👉🏼 plaque progression prevention European Atherosclerosis Society EAS Congress #medtwitter #cardiotwitter

👉Advances in Targeting LDL Cholesterol: PCSK9 Inhibitors and Beyond 👏 Outstanding article, great authors, must-read!!! ☝️Multiple advanced treatments are currently available to address residual atherogenic lipoprotein risk beyond statin therapy. With every approximately 40

Study of #semaglutide vs #tirzepatide for weight loss. Tirzepide is the clear winner in terms of percentage of weight lost and number of participants who lost at least 10%. JAMA Internal Medicine jamanetwork.com/journals/jamai…

Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation ☑️ Lp(a) resulted in an additional 0.32% increment in percent atheroma volume for every 10 years of follow-up. jamanetwork.com/journals/jamac…

Spanish consensus on Practical use of new therapies for the management of dyslipidaemias. Soc Esp Cardiología REC Publications David Vivas Gonzalo Barón Rosa Fernandez LipidMIR sciencedirect.com/science/articl…

For almost two decades, 12-month DAPT in ACS has been the only class I recommendation on DAPT in American and European guidelines, despite the lack of prospectively established evidence. Several subsequent studies questioned the 12-month regimen and suggested that DAPT duration

Nuestro nuevo artículo: Diseño del estudio CAPRICI. Estudio aleatorizado, controlado, prospectivo y multicéntrico 🩺📈 sciencedirect.com/science/articl… Sergio Cinza José R. Juanatey Daniel Rey Aldana Palo Sempere Manuel Portela Romero José R. Juanatey 👏👏

Continuidad asistencial entre cardiología y AP en pacientes con cardiopatía isquémica crónica: diseño del estudio CAPRICI #reccardioclinics #AheadOfPrint Sergio Cinza Jose Seijas Amigo José R. Juanatey reccardioclinics.org//es-continuida…